Feb 14, 2024
 in 
Hot Stocks 🔥

Diabetes and weight loss drug market expected to soar to $100bn by 2030

Name of opportunity: 👀

Novo Nordisk A/S 

Flying off the shelves: 💸

Analysts say the diabetes and weight loss market will be worth $100bn by 2030, which means Novo Nordisk A/S could be a great investment. The pharmaceutical company’s product range includes Saxenda, their brand name for liraglutide, a drug similar to Ozempic. 

This type of drug has seen enormous popularity over the last year. While often used as a treatment for type 2 diabetes, its use as a weight loss drug has everyone talking. This product has been flying off shelves around the world at such a speed that some countries are running low on supplies, which just goes to show how popular this drug is. 

How hot is this investment opportunity? 🔥🔥🔥

Analysts see it as a Buy.

Novo Nordisk A/S has steadily risen in value over the last year. 

Analysts predict that Novo Nordisk A/S will increase in value over the next 12 months by 1.98%, from $120.38 to $122.81. 

Snapshot of the company: 📸

This is a solid company with a very long history, dating back to the 1920s when Nordisk Insulinlaboratorium started commercially producing insulin. 

The value of Novo Nordisk hit a new record high in 2023. Since then, through a $16.5bn deal, Novo Nordisk has acquired three sites previously owned by pharma manufacturers Catalent in order to increase production. It seems they are feeling confident and aiming to scale - suggesting this could be a great time to invest. 

Which neme?: 🔍

You can find this stock in the Pharma neme.

Han Tan

Han Tan is Chief Market Analyst at Nemo.money, bringing over a decade of experience in financial markets as both a seasoned journalist and analyst. Known for his sharp insights into stocks, currencies, and commodities, Han has become a familiar face to national audiences through appearances on Bloomberg TV Malaysia, BFM 89.9, and NTV7 — earning him a trusted reputation in financial media. Before joining Nemo, Han served as Market Analyst at Exinity Group from 2019, where his commentary on macroeconomic trends and market-moving news was regularly featured by global outlets including Reuters, Bloomberg, CNN, BBC, and AFP. Today, Han brings that same clarity and depth to Nemo’s community, delivering content-led ideas that empower first-time investors to confidently navigate global markets.